Relay Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company focused on transforming the drug discovery process. The company's proprietary Dynamo platform integrates computational and experimental approaches—including structural biology, biophysics, chemistry, and machine learning—to study protein motion and design therapies targeting previously intractable or inadequately addressed disease-causing proteins. Relay's lead clinical asset is zovegalisib (RLY-2608), a pan-mutant selective PI3Kα inhibitor currently in Phase 3 clinical development (ReDiscover-2) for HR+/HER2- metastatic breast cancer. The company is also advancing RLY-8161, an NRAS-selective inhibitor in Phase 1 development for solid tumors, and has out-licensed lirafugratinib (RLY-4008), an FGFR2 inhibitor, to Elevar Therapeutics.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Shifting strategic focus from a platform-discovery company to a late-stage clinical execution company, prioritizing the global Phase 3 development of lead candidate zovegalisib (RLY-2608).
Expected impact: Aims to de-risk the pipeline, achieve regulatory approvals, and capture a multi-billion dollar market share in precision oncology.
Implementing disciplined cost-saving measures, including workforce reductions and narrowing the research portfolio to focus on the highest-value clinical programs.
Expected impact: Successfully extended the company's cash runway into 2029, ensuring full funding for key clinical value drivers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To accelerate the application of machine learning across Relay's Dynamo platform, fast-tracking the discovery of novel medicines against intractable targets.
Financial impact: Upfront payment of $85 million ($20 million in cash and $65 million in common stock), with up to an additional $85 million in platform and program-related milestones.
Strategic Partnerships
Grants Elevar worldwide rights to develop and commercialize lirafugratinib (RLY-4008), allowing Relay to remain fully focused on advancing its core PI3Kα programs.
Terms: Relay is eligible to receive up to $500 million in total payments, including $75 million in upfront and regulatory milestones, plus up to $425 million in potential commercial milestones and tiered royalties up to the low-teens percentage.
To evaluate Pfizer's investigational selective-CDK4 inhibitor, atirmociclib, in combination with Relay's zovegalisib (RLY-2608) and fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.
Terms: Pfizer provides atirmociclib for use in the study at no cost, while Relay is responsible for conducting the clinical trials.